Interferon-Beta-1a (FP-1201) to Prevent Toxicities After CD19-Directed CAR T-Cell Therapy

Conditions:   Recurrent B Acute Lymphoblastic Leukemia;   Recurrent B-Cell Non-Hodgkin Lymphoma;   Refractory B Acute Lymphoblastic Leukemia;   Refractory B-Cell Non-Hodgkin Lymphoma;   Recurrent Mantle Cell Lymphoma;   Refractory Mantle Cell Lymphoma Interventions:   Biological: Interferon Beta-1A;   Procedure: X-Ray Imaging;   Procedure: Echocardiography;   Procedure: Multigated Acquisition Scan;   Procedure: Computed Tomography;   Procedure: Positron Emission Tomography;   Procedure: Lumbar Puncture;   Procedure: Bone Marrow Aspira tion;   Procedure: Bone Marrow Biopsy;   Procedure: Biospecimen Collection;   Procedure: Biopsy Sponsors:   Fred Hutchinson Cancer Center;   Faron Pharmaceuticals Ltd Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials